<p>可以说，<strong>中集安瑞科</strong>（HKG:3899）目前的市盈率为 12.6 倍，相较于香港市场的中位数市盈率约为 12 倍，显得相当 “中规中矩”。然而，如果市盈率没有合理的基础，投资者可能会忽视一个明显的机会或潜在的挫折。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行探索。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p>中集安瑞科最近的表现确实不错，其盈利增长超过了大多数其他公司。一个可能性是，市盈率适中是因为投资者认为这种强劲的盈利表现可能即将减弱。如果你喜欢这家公司，你会希望这种情况不会发生，以便在它还未受到青睐时能够买入一些股票。</p>
<p>查看我们对中集安瑞科的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/23554652-pe-multiple-vs-industry-1-dark-2/1764562581497?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/23554652-pe-multiple-vs-industry-1-dark-2/1764562581497"/></p>
<p>SEHK:3899 市盈率与行业比较 2025 年 12 月 1 日</p>
<p>如果你想了解分析师对未来的预测，可以查看我们关于中集安瑞科的 <strong>免费</strong> 报告。</p>
<h2>中集安瑞科的增长趋势如何？</h2>
<p>中集安瑞科的市盈率对于一家预计仅能实现适度增长的公司来说是典型的，重要的是，它的表现与市场保持一致。</p>
<p>回顾过去一年，该公司的净利润增长了 13%。最近三年期间，EPS 整体上升了 23%，在一定程度上得益于其短期表现。因此，可以公平地说，该公司的盈利增长在最近是相当可观的。</p>
<p>展望未来，预计未来三年将实现每年 13% 的增长，这是由关注该公司的 11 位分析师的估计得出的。同时，市场的其他部分预计将每年增长 15%，这显然更具吸引力。</p>
<p>考虑到这一点，令人好奇的是，中集安瑞科的市盈率与大多数其他公司相当。似乎大多数投资者忽视了相对有限的增长预期，并愿意为接触该股票支付更高的价格。如果市盈率降至与增长预期更为一致的水平，这些股东可能会为未来的失望埋下伏笔。</p>
<h2>关键要点</h2>
<p>通常情况下，我们会警惕在做出投资决策时过度解读市盈率，尽管它可以揭示其他市场参与者对公司的看法。</p>
<p>我们对中集安瑞科分析师预测的审查显示，其较差的盈利前景并没有像我们预期的那样影响其市盈率。目前我们对市盈率感到不安，因为预测的未来盈利不太可能长期支持更积极的市场情绪。除非这些条件改善，否则很难接受这些价格是合理的。</p>
<p>值得注意的是，我们发现 <strong>中集安瑞科有 1 个警示信号</strong>，你需要考虑这一点。</p>
<p>如果这些 <strong>风险让你重新考虑对中集安瑞科的看法</strong>，可以浏览我们的高质量股票互动列表，以了解还有哪些其他选择。</p>

中集安瑞科

<p>中集安瑞科控股有限公司的市盈率为 12.6 倍，在香港市场上被视为平均水平。尽管盈利增长可观，分析师预测其增长速度将低于市场水平。如果增长预期未能实现，投资者可能会高估该股票，面临未来失望的风险。该公司的市盈率并未反映其较差的盈利前景，这引发了对其当前估值的担忧</p>

<p>It's not a stretch to say that <strong>CIMC Enric Holdings Limited's</strong> (HKG:3899) price-to-earnings (or &#34;P/E&#34;) ratio of 12.6x right now seems quite &#34;middle-of-the-road&#34; compared to the market in Hong Kong, where the median P/E ratio is around 12x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/E.</p>
<div class="lb-trans"><p>可以说，<strong>中集安瑞科</strong>（HKG:3899）目前的市盈率为 12.6 倍，相较于香港市场的中位数市盈率约为 12 倍，显得相当 “中规中矩”。然而，如果市盈率没有合理的基础，投资者可能会忽视一个明显的机会或潜在的挫折。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行探索。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p>CIMC Enric Holdings certainly has been doing a good job lately as it's been growing earnings more than most other companies. One possibility is that the P/E is moderate because investors think this strong earnings performance might be about to tail off. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's not quite in favour.</p>
<div class="lb-trans"><p>中集安瑞科最近的表现确实不错，其盈利增长超过了大多数其他公司。一个可能性是，市盈率适中是因为投资者认为这种强劲的盈利表现可能即将减弱。如果你喜欢这家公司，你会希望这种情况不会发生，以便在它还未受到青睐时能够买入一些股票。</p>
</div><p>Check out our latest analysis for CIMC Enric Holdings</p>
<div class="lb-trans"><p>查看我们对中集安瑞科的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/23554652-pe-multiple-vs-industry-1-dark-2/1764562581497" alt="" original-src="https://images.simplywall.st/asset/chart/23554652-pe-multiple-vs-industry-1-dark-2/1764562581497"/></p>
<p>SEHK:3899 Price to Earnings Ratio vs Industry December 1st 2025</p>
<div class="lb-trans"><p>SEHK:3899 市盈率与行业比较 2025 年 12 月 1 日</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on CIMC Enric Holdings.</p>
<div class="lb-trans"><p>如果你想了解分析师对未来的预测，可以查看我们关于中集安瑞科的 <strong>免费</strong> 报告。</p>
</div><h2>How Is CIMC Enric Holdings' Growth Trending?</h2>
<div class="lb-trans"><h2>中集安瑞科的增长趋势如何？</h2>
</div><p>CIMC Enric Holdings' P/E ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the market.</p>
<div class="lb-trans"><p>中集安瑞科的市盈率对于一家预计仅能实现适度增长的公司来说是典型的，重要的是，它的表现与市场保持一致。</p>
</div><p>Retrospectively, the last year delivered a decent 13% gain to the company's bottom line. The latest three year period has also seen a 23% overall rise in EPS, aided somewhat by its short-term performance. Therefore, it's fair to say the earnings growth recently has been respectable for the company.</p>
<div class="lb-trans"><p>回顾过去一年，该公司的净利润增长了 13%。最近三年期间，EPS 整体上升了 23%，在一定程度上得益于其短期表现。因此，可以公平地说，该公司的盈利增长在最近是相当可观的。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 13% per year as estimated by the eleven analysts watching the company. Meanwhile, the rest of the market is forecast to expand by 15% per year, which is noticeably more attractive.</p>
<div class="lb-trans"><p>展望未来，预计未来三年将实现每年 13% 的增长，这是由关注该公司的 11 位分析师的估计得出的。同时，市场的其他部分预计将每年增长 15%，这显然更具吸引力。</p>
</div><p>In light of this, it's curious that CIMC Enric Holdings' P/E sits in line with the majority of other companies. It seems most investors are ignoring the fairly limited growth expectations and are willing to pay up for exposure to the stock. These shareholders may be setting themselves up for future disappointment if the P/E falls to levels more in line with the growth outlook.</p>
<div class="lb-trans"><p>考虑到这一点，令人好奇的是，中集安瑞科的市盈率与大多数其他公司相当。似乎大多数投资者忽视了相对有限的增长预期，并愿意为接触该股票支付更高的价格。如果市盈率降至与增长预期更为一致的水平，这些股东可能会为未来的失望埋下伏笔。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><p>Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.</p>
<div class="lb-trans"><p>通常情况下，我们会警惕在做出投资决策时过度解读市盈率，尽管它可以揭示其他市场参与者对公司的看法。</p>
</div><p>Our examination of CIMC Enric Holdings' analyst forecasts revealed that its inferior earnings outlook isn't impacting its P/E as much as we would have predicted. Right now we are uncomfortable with the P/E as the predicted future earnings aren't likely to support a more positive sentiment for long. Unless these conditions improve, it's challenging to accept these prices as being reasonable.</p>
<div class="lb-trans"><p>我们对中集安瑞科分析师预测的审查显示，其较差的盈利前景并没有像我们预期的那样影响其市盈率。目前我们对市盈率感到不安，因为预测的未来盈利不太可能长期支持更积极的市场情绪。除非这些条件改善，否则很难接受这些价格是合理的。</p>
</div><p>It is also worth noting that we have found <strong>1 warning sign for CIMC Enric Holdings</strong> that you need to take into consideration.</p>
<div class="lb-trans"><p>值得注意的是，我们发现 <strong>中集安瑞科有 1 个警示信号</strong>，你需要考虑这一点。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on CIMC Enric Holdings</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果这些 <strong>风险让你重新考虑对中集安瑞科的看法</strong>，可以浏览我们的高质量股票互动列表，以了解还有哪些其他选择。</p>
</div>

中集安瑞科控股有限公司（HKG:3899）的业务表现尚未与其股价相匹配